Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX BIIB AMZN IBB TSLA ALXN ILMN WYNN AMGN GMCR SLXP COST Z VRTX GILD AAPL CELG WDC
Nyse: ACT V LNKD IVV PXD AGN LMT GS SPG FDX IBM MMM TWC CMI GD APD NOC PX BDX BA
New Highs: REGN IBB MCK ALXN SPG ORLY WHR BCR MMM IDXX GD EW UNP SLG GILD PANW AAPL CELG CLX TRV

The Hot Industries

Biotechnology 4
REIT - Retail 2
Railroads 1

The Hot Sectors

Healthcare 7
Consumer Goods 3
Financial 3

ARIA Stock Chart


ARIA
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

307
Monthly

Website:

http://www.ariad.com

ARIA Ariad Pharmaceuticals Inc.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

favicon

InPlay from Briefing.com

24 Oct 2014, 1:51 pmInPlay from Briefing.com
favicon

Kings Cross to welcome rock star royalty

15 Oct 2014, 1:01 pmThe X Studio aims to bring A-list celebrities into Sydney's Kings Cross to record, broadcast and party.
favicon

ARIAD's Iclusig Gains Positive Recommendation from PRAC

14 Oct 2014, 2:55 pmAriad Pharmaceuticals Inc. (ARIA) announced that the PRAC issued a positive feedback in favor of Iclusig and that it can be continued to be used in Europe.
favicon

Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog

13 Oct 2014, 5:31 pmInvestors in the pharma biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give
favicon

Fat Lady Is About to Sing, According to the Charts

8 Oct 2014, 2:42 pmToday’s rally doesn’t erase the bearish signals from recent market action, including small stock weakness.
favicon

ARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog

6 Oct 2014, 5:30 pmARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog
favicon

ARIAD Gets Breakthrough Therapy Designation for AP26113

6 Oct 2014, 2:55 pmAriad Pharmaceuticals Inc. (ARIA) announced that the FDA has granted Breakthrough Therapy designation to its lung cancer candiadate, AP26113 for the treatment of ALK+ non-small cell lung cancer (NSCLC)....
favicon

Why Ariad Pharmaceuticals (ARIA) Stock Is Spiking Today

2 Oct 2014, 9:59 amNEW YORK (TheStreet) -- Ariad Pharmaceuticals shares are up 8.6% to $5.74 on Thursday after the company announced that its experimental lung cancer drug received a "breakthrough therapy" designation from the FDA. A "breakthrough therapy designation" means that the FDA can fast track the review process for aadrug that shows evidence of being an improvement of current treatments for patients with ...
favicon

Bulls Target Ariad Pharmaceuticals, Inc. (ARIA) Amid Drug News

2 Oct 2014, 9:44 amAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) gapped higher this morning on news that its lung cancer drug, ... ( Read More )
favicon

How one trader is betting on Ariad

30 Sep 2014, 4:45 amOne trader is betting on a pop in shares of Ariad Pharmaceuticals by early next year. optionMONSTER's Heat Seeker system detected the purchase of 2,500 January 6 calls for $0.80 and $0.90 at the same second ...